Amgen’s Bottom Appears To Be In – Buy Now

AMGN flashed multiple buy signals last week


Amgen (AMGN) — This biotech company has been a leader in the development of genetically based research and treatment for cancer, anemia, rheumatoid arthritis and a host of other major illnesses. It markets a number of the world’s best-selling biotech drugs.

Analysts expect earnings to increase to $8.09 per share in 2014 from $7.60 in 2013, and they anticipate $8.78 in 2015. The 12-month consensus median price target is $31.

AMGN broke from a cup-and-handle formation and advanced from $110 to $128.96 before succumbing to the sell-off in biotech stocks, which took it 14% off its high. But last week, it appeared to pick up buyers as MACD flashed a buy signal, and the second buy signal from my proprietary Collins-Bollinger Reversal (CBR ) indicator in two weeks was triggered on Friday.

Buy AMGN with a trading target of $120. Long-term investors could be rewarded with much higher returns from this leading biotech company.

05 12 14 amgn 300x188 Amgens Bottom Appears To Be In   Buy Now
Click to Enlarge

chart key 300x84 Amgens Bottom Appears To Be In   Buy Now

Article printed from InvestorPlace Media,

©2015 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.